fosfomycin and Lung-Diseases--Interstitial

fosfomycin has been researched along with Lung-Diseases--Interstitial* in 1 studies

Other Studies

1 other study(ies) available for fosfomycin and Lung-Diseases--Interstitial

Article	Year
Changes in serum KL-6 after intravenous fosfomycin administration in idiopathic interstitial pneumonia. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2004, Volume: 10, Issue:1 Changes in serum KL-6 levels after intravenous fosfomycin (FOM) administration in idiopathic interstitial pneumonia (IIP) were studied. Seventeen patients who were diagnosed with usual interstitial pneumonia by surgical lung biopsy were selected as subjects. In these patients, FOM was administered intravenously, at a dose of 2 g twice daily, for 14 days, and serum KL-6 was determined before and after its administration. FOM administration resulted in a reduction of serum KL-6 in all 17 patients (1273 +/- 132 U/ml [mean +/- SEM] to 1023 +/- 101 U/ml; P < 0.01). FOM may reduce serum KL-6 in IIP and may be an appropriate therapeutic drug for this condition. Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens; Antigens, Neoplasm; Biomarkers; Female; Fosfomycin; Glycoproteins; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Mucins; Treatment Outcome	2004

Article

Year

Changes in serum KL-6 after intravenous fosfomycin administration in idiopathic interstitial pneumonia.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2004, Volume: 10, Issue:1

Changes in serum KL-6 levels after intravenous fosfomycin (FOM) administration in idiopathic interstitial pneumonia (IIP) were studied. Seventeen patients who were diagnosed with usual interstitial pneumonia by surgical lung biopsy were selected as subjects. In these patients, FOM was administered intravenously, at a dose of 2 g twice daily, for 14 days, and serum KL-6 was determined before and after its administration. FOM administration resulted in a reduction of serum KL-6 in all 17 patients (1273 +/- 132 U/ml [mean +/- SEM] to 1023 +/- 101 U/ml; P < 0.01). FOM may reduce serum KL-6 in IIP and may be an appropriate therapeutic drug for this condition.

Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens; Antigens, Neoplasm; Biomarkers; Female; Fosfomycin; Glycoproteins; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Male; Middle Aged; Mucin-1; Mucins; Treatment Outcome

2004